Recursion Pharmaceuticals Inc (RXRX)
8.335
+0.52
(+6.72%)
USD |
NASDAQ |
May 01, 16:00
8.40
+0.06
(+0.78%)
After-Hours: 20:00
Recursion Pharmaceuticals Revenue (Quarterly): 10.62M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.62M |
| September 30, 2023 | 10.10M |
| June 30, 2023 | 11.02M |
| March 31, 2023 | 12.13M |
| December 31, 2022 | 13.68M |
| September 30, 2022 | 13.05M |
| June 30, 2022 | 7.653M |
| Date | Value |
|---|---|
| March 31, 2022 | 5.299M |
| December 31, 2021 | 2.50M |
| September 30, 2021 | 2.50M |
| June 30, 2021 | 2.50M |
| March 31, 2021 | 2.50M |
| December 31, 2020 | 2.551M |
| September 30, 2020 | 0.862M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.862M
Minimum
Sep 2020
13.68M
Maximum
Dec 2022
6.926M
Average
6.476M
Median
Revenue (Quarterly) Benchmarks
| Eli Lilly and Co | 9.353B |
| Palatin Technologies Inc | 2.034M |
| Oragenics Inc | -- |
| Actinium Pharmaceuticals Inc | 0.081M |
| Marinus Pharmaceuticals Inc | 7.19M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -93.00M |
| Total Expenses (Quarterly) | 109.55M |
| EPS Diluted (Quarterly) | -0.42 |
| Enterprise Value | 1.442B |
| Gross Profit Margin (Quarterly) | 6.99% |
| Profit Margin (Quarterly) | -875.3% |
| Earnings Yield | -18.84% |
| Normalized Earnings Yield | -18.84 |